<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679129</url>
  </required_header>
  <id_info>
    <org_study_id>ASC42-I-CTP-01</org_study_id>
    <nct_id>NCT04679129</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, Single Center Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics (Biomarkers) of ASC42 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gannex Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gannex Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first in human study of single and multiple ascending doses and food effect of&#xD;
      ASC42.&#xD;
&#xD;
      This study consists of 8 cohorts and is divided as follows:&#xD;
&#xD;
      Part Ia: Single ascending doses study including cohorts 1 to 5. Part Ib: A cross-over design&#xD;
      of cohort 2 to study the food effect on ASC42 PK. Part II: Multiple ascending doses study&#xD;
      including cohorts 6 to 8.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Actual">June 3, 2021</completion_date>
  <primary_completion_date type="Actual">May 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Occurrence of Serious Adverse Event (SAE), Adverse Event (AE) resulting in treatment discontinuation and/or dose reductions, and AE of special interest, from baseline up to 21 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of ASC42</measure>
    <time_frame>On Day 1 to Day 14 after single or multiple doses, respectively. The entire study will last up to 15 days.</time_frame>
    <description>Evaluate the Area under the plasma concentration versus time curve after single and multiple oral doses of ASC42 administered to healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of ASC42</measure>
    <time_frame>On Day 1 to Day 14 after single or multiple doses, respectively. The entire study will last up to 15 days.</time_frame>
    <description>Evaluate the Peak Plasma Concentration after single and multiple oral doses of ASC42 administered to healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of ASC42</measure>
    <time_frame>On Day 1 to Day 14 after single or multiple doses, respectively. The entire study will last up to 15 days.</time_frame>
    <description>Evaluate the Terminal-Phase Half-Life after single and multiple oral doses of ASC42 administered to healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of ASC42</measure>
    <time_frame>On Day 1 to Day 14 after single or multiple doses, respectively. The entire study will last up to 15 days.</time_frame>
    <description>Evaluate the Apparent Systemic Clearance after single and multiple oral dose of ASC42 administered to healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of ASC42</measure>
    <time_frame>On Day 1 to Day 14 after single or multiple doses, respectively. The entire study will last up to 15 days.</time_frame>
    <description>Evaluate the Apparent Volume of Distribution after single and multiple oral dose of ASC42 administered to healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of ASC42</measure>
    <time_frame>On Day 1 to Day 14 after single or multiple doses, respectively. The entire study will last up to 15 days.</time_frame>
    <description>Evaluate the Time to reach the maximum plasma concentration after single single and multiple oral doses of ASC42 administered to healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C4</measure>
    <time_frame>On Day 1 to Day 14 after single or multiple doses, respectively. The entire study will last up to 15 days.</time_frame>
    <description>Bile acid precuisor:C4 (7αhydroxy-4-cholesten-3-one)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FGF19</measure>
    <time_frame>On Day 1 to Day 14 after single or multiple doses, respectively. The entire study will last up to 15 days.</time_frame>
    <description>Bile acid precursor:FGF19 (Fibroblast growth factor 19)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose-ASC42</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC42 tablet，Dose 1，Dose 2，Dose 3，Dose 4，and Dose 5, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose-ASC42</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC42 tablet, Dose 1，Dose 2，Dose 3，q.d.×14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet，Dose 1，Dose 2，Dose 3，Dose 4，and Dose 5, single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet，Dose 1，Dose 2，Dose 3，q.d.×14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC42</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Multiple Ascending Dose-ASC42</arm_group_label>
    <arm_group_label>Single Ascending Dose-ASC42</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Multiple Ascending Dose-Placebo</arm_group_label>
    <arm_group_label>Single Ascending Dose-Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects between 18 to 65 years of age.&#xD;
&#xD;
          -  Subjects' weight ≥ 50 kg and BMI within the range of 19 - 29 kg/m2.&#xD;
&#xD;
          -  Physical examination and vital signs are within normal range or slightly abnormal.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History or current liver disease, or liver injuries.&#xD;
&#xD;
          -  A positive HBsAg, HCV Ab and/or HIV Ab.&#xD;
&#xD;
          -  Platelet count &lt;150,000/mcL&#xD;
&#xD;
          -  INR&gt; 1.2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ICON early Phase Services LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

